Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CLPP | Q16740 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5983378 | 0.90 | MEN1 (0.36) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL5982667 | 0.82 | MEN1 (0.36) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL20548792 | 0.78 | MEN1 (0.44) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL791333 | 0.77 | GAA (0.57) | KDM4EGAAPOLB | |
| SCHEMBL29469069 | 0.77 | GAA (0.57) | KDM4EGAAPOLB | |
| SCHEMBL31255732 | 0.76 | GAA (0.37) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL31255734 | 0.76 | GAA (0.37) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL3784749 | 0.73 | HPGD (0.62) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL4763194 | 0.73 | PTGS2 (0.43) | KMT2AALDH1A1KDM4ELMNAHSD17B10 | |
| SCHEMBL28063627 | 0.72 | ENPP2 (0.40) | MEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082877-A1 | Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof | BAYER CORPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-04-12 | — | — | US | claimed |
| US-20070082877-A1 | Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof | BAYER CORPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082877-A1 | Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof | FBL, Q6ZSR9, DDT | MEN1 772/4885KMT2A 1279/4885ALDH1A1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.